Lv2
136 积分 2023-12-25 加入
Strategies of targeting CYP51 for IFIs therapy: Emerging prospects, opportunities and challenges
23小时前
待确认
Oteseconazole: First Approved Orally Bioavailable and Selective CYP51 Inhibitor for the Treatment of Patients with Recurrent Vulvovaginal Candidiasis
1天前
已完结
State-of-the-art of vulvovaginal candidiasis: etiopathogenesis, diagnosis, and treatment
1天前
求助中
Azole antifungals: 35 years of invasive fungal infection management
1天前
已关闭
Recent drug development and treatments for fungal infections
1天前
已完结
Oteseconazole (VIVOJA) for prevention of recurrent vulvovaginal candidiasis
1天前
已完结
Oteseconazole: a long-awaited diversification of the antifungal arsenal to manage recurrent vulvovaginal candidiasis (RVVC)
1天前
已完结
Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial
2天前
已完结
Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): final results of a randomised phase 3 study
2天前
已完结
Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): final results of a randomised phase 3 study
2天前
已完结
皖公网安备34019202002308
